( v> The Jikei Heart Study is thefirst ...)Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study,Health

The Jikei Heart Study is the first controlled trial to assess the cardiovascular benefits of adding the angiotensin receptor blocker (ARB) Diovan to conventional non-ARB therapy, compared to non-ARB therapy alone, in a large Japanese population. Key events evaluated as part of the primary endpoint included heart attack, stroke and hospitalization for heart failure or angina pectoris.

The study was conceived, designed, and conducted by an investigator-led steering committee, representing the Jikei Executive Committee and the hospitals involved with the trial. The study was funded by the Jikei University School of Medicine in Tokyo with an unrestricted grant from Novartis. Novartis had no role in study design, data collection, data analysis, data interpretation or writing of the report.

"Innovative clinical trials have helped Diovan to advance cardiovascular patient care," said Ameet Nathwani, MD, Global Head of Cardiovascular and Metabolic Clinical Research, Development and Medical Affairs, Novartis Pharma AG. "The results of the independent Jikei Heart Study add to the already large body of evidence demonstrating Diovan's efficacy in lowering blood pressure and preventing cardiovascular events."

The Jikei Heart Study1 was a multi-center controlled clinical trial with a prospective randomized open-label blinded endpoint (PROBE) design. It was conducted by the Jikei University School of Medicine in Tokyo in 3,081 people aged 20 to 79 years with high blood pressure, ischemic heart disease or congestive heart failure. There were no significant differences in blood pressure or heart rate between the treatment groups.'"/>




Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
2. Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
9. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus